PL2219665T3 - Preparaty parathormonu i ich zastosowanie - Google Patents

Preparaty parathormonu i ich zastosowanie

Info

Publication number
PL2219665T3
PL2219665T3 PL08842081T PL08842081T PL2219665T3 PL 2219665 T3 PL2219665 T3 PL 2219665T3 PL 08842081 T PL08842081 T PL 08842081T PL 08842081 T PL08842081 T PL 08842081T PL 2219665 T3 PL2219665 T3 PL 2219665T3
Authority
PL
Poland
Prior art keywords
pth
parathyroid hormone
formulations
ionic surfactant
hormone formulations
Prior art date
Application number
PL08842081T
Other languages
English (en)
Inventor
Linderoth Dorte Loer
Hansen Lars Lindegaard
Original Assignee
Takeda Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharma As filed Critical Takeda Pharma As
Publication of PL2219665T3 publication Critical patent/PL2219665T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL08842081T 2007-10-26 2008-10-27 Preparaty parathormonu i ich zastosowanie PL2219665T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99606107P 2007-10-26 2007-10-26
EP07021017A EP2052736A1 (en) 2007-10-26 2007-10-26 Parathyroid hormone formulations und uses thereof
PCT/EP2008/009069 WO2009053106A1 (en) 2007-10-26 2008-10-27 Parathyroid hormone formulations and uses thereof
EP08842081A EP2219665B1 (en) 2007-10-26 2008-10-27 Parathyroid hormone formulations and uses thereof

Publications (1)

Publication Number Publication Date
PL2219665T3 true PL2219665T3 (pl) 2011-11-30

Family

ID=39146901

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08842081T PL2219665T3 (pl) 2007-10-26 2008-10-27 Preparaty parathormonu i ich zastosowanie

Country Status (14)

Country Link
EP (2) EP2052736A1 (pl)
AT (1) ATE501725T1 (pl)
CY (1) CY1112106T1 (pl)
DE (1) DE602008005643D1 (pl)
DK (1) DK2219665T3 (pl)
ES (1) ES2363272T3 (pl)
HR (1) HRP20110444T1 (pl)
MX (1) MX2010004388A (pl)
PL (1) PL2219665T3 (pl)
PT (1) PT2219665E (pl)
RU (1) RU2467762C2 (pl)
SI (1) SI2219665T1 (pl)
WO (1) WO2009053106A1 (pl)
ZA (1) ZA201002812B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2699252B1 (en) * 2011-04-22 2017-10-25 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
CN108892709A (zh) * 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
KR102143482B1 (ko) 2011-11-30 2020-08-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치, 이의 제조 및 사용 방법
WO2014027281A1 (en) * 2012-08-13 2014-02-20 Koninklijke Philips N.V. Use of antioxidants in methods and means for detection of target molecules in a blood sample
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
GB201602880D0 (en) 2016-02-18 2016-04-06 Ge Healthcare Uk Ltd Method and composition for biomolecule stabilization
MY208384A (en) 2016-03-01 2025-05-05 Ascendis Pharma Bone Diseases As Pth prodrugs
US12453778B2 (en) 2016-09-29 2025-10-28 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release PTH compounds
HRP20230383T1 (hr) 2016-09-29 2023-07-07 Ascendis Pharma Bone Diseases A/S Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji
KR102627405B1 (ko) 2016-09-29 2024-01-18 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ,インコーポレイテッド Rad1901-2hclの多形性形態
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
KR20210038618A (ko) * 2018-07-30 2021-04-07 샤이어-엔피에스 파마슈티칼즈, 인크. 재조합 인간 부갑상선 호르몬의 개선된 안정성을 위한 제형
MY209748A (en) * 2019-02-11 2025-07-31 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
EP4110370A4 (en) * 2020-03-30 2023-06-07 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. HUMAN PARATHYROID HORMONE (PTH) FORMULATIONS AND METHODS OF PRODUCING THEM
CN113101275A (zh) * 2021-05-27 2021-07-13 海南通用康力制药有限公司 注射用棓丙酯冻干粉针剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0643981B1 (en) * 1993-09-22 2002-01-09 Hisamitsu Pharmaceutical Co., Inc. A matrix for iontophoreses
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
KR101235507B1 (ko) * 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
KR20070010115A (ko) * 2003-11-13 2007-01-22 알자 코포레이션 경피전달용 조성물 및 장치
EP1931374A2 (en) * 2005-10-06 2008-06-18 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products

Also Published As

Publication number Publication date
RU2010121165A (ru) 2011-12-10
CY1112106T1 (el) 2015-11-04
ZA201002812B (en) 2011-12-28
EP2219665A1 (en) 2010-08-25
RU2467762C2 (ru) 2012-11-27
MX2010004388A (es) 2010-08-10
DE602008005643D1 (de) 2011-04-28
ES2363272T3 (es) 2011-07-28
ATE501725T1 (de) 2011-04-15
EP2052736A1 (en) 2009-04-29
HK1146465A1 (en) 2011-06-10
WO2009053106A1 (en) 2009-04-30
PT2219665E (pt) 2011-06-29
SI2219665T1 (sl) 2011-09-30
EP2219665B1 (en) 2011-03-16
DK2219665T3 (da) 2011-06-27
HRP20110444T1 (hr) 2011-08-31

Similar Documents

Publication Publication Date Title
ZA201002812B (en) Parathyroid hormone formulations and uses thereof
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
AR064614A1 (es) Producto combinado par controlar parasitos en animales
BR112015023391A8 (pt) formulações de conjugados anticorpo-droga anti-egfr
MY167560A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
WO2009117130A3 (en) Extended release forumulation containing a wax
WO2011061330A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
WO2006069241A3 (en) Methods for promoting oral health in animals
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
MY161595A (en) Oral care compositions
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
PH12012501620A1 (en) Oral care compositions
WO2011140232A3 (en) Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
WO2010021607A3 (en) Pharmaceutical formulation
WO2017127835A3 (en) Aqueous formulations and methods of preparation and use thereof
WO2011017054A3 (en) Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
TN2011000261A1 (en) Octreotide depot formulation with constantly high exposure levels
MX355885B (es) Composición farmacéutica de administración oral.
EP1993567A4 (en) PER OS ADMINISTRABLE GALLIUM PREPARATIONS AND METHODS OF USE
WO2006096518A3 (en) Improved gacyclidine formulations
MX2010008365A (es) Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido.
WO2013170086A3 (en) Formulations for the delivery of active ingredients